U.S. Breast Cancer Diagnostics Market Size & Outlook
U.S. breast cancer diagnostics market, 2018-2030 (US$M)
Related Markets
U.S. breast cancer diagnostics market highlights
- The U.S. breast cancer diagnostics market generated a revenue of USD 2,261.5 million in 2024 and is expected to reach USD 3,417.5 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7.2% from 2025 to 2030.
- In terms of segment, imaging was the largest revenue generating type in 2024.
- Blood Tests is the most lucrative type segment registering the fastest growth during the forecast period.
Breast cancer diagnostics market data book summary
| Market revenue in 2024 | USD 2,261.5 million |
| Market revenue in 2030 | USD 3,417.5 million |
| Growth rate | 7.2% (CAGR from 2025 to 2030) |
| Largest segment | Imaging |
| Fastest growing segment | Blood Tests |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Imaging, Biopsy, Genomic Tests, Blood Tests |
Other key industry trends
- In terms of revenue, U.S. accounted for 41.3% of the global breast cancer diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. breast cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 350.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Cancer Diagnostics Market Scope
Breast Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. breast cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer diagnostics market will help companies and investors design strategic landscapes.
Imaging was the largest segment with a revenue share of 54.78% in 2024. Horizon Databook has segmented the U.S. breast cancer diagnostics market based on imaging, biopsy, genomic tests, blood tests covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. held the largest market share of breast cancer diagnostics market in North America. The growth can be attributed to the increasing prevalence of breast cancer and rising government initiatives aimed at enhancing screening & diagnostic rates in the country.
For instance, in January 2024, Weill Cornell Medicine received a $2.4 million grant from the U.S. Department of Defense to validate the Syantra DX Breast Cancer test, a blood-based diagnostic tool using AI to detect breast cancer at an early stage.
This liquid biopsy aims to improve screening, particularly for high-risk women, those with dense breast tissue, and underserved populations, offering a non-invasive alternative to mammograms. The Syantra DX test could revolutionize breast cancer screening by increasing accessibility, especially for women with dense breast tissue and those in remote areas.
Reasons to subscribe to U.S. breast cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. breast cancer diagnostics market databook
-
Our clientele includes a mix of breast cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. breast cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. breast cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. breast cancer diagnostics market size, by type, 2018-2030 (US$M)
U.S. Breast Cancer Diagnostics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
